Research location
Livingston
New Jersey, United States
Advertisement
Research activity in Livingston
New Jersey, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 140 trials and 141 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Livingston
140 linked trials · page 1 of 3A Study of Orelabrutinib in Patients With Primary Progressive Multiple SclerosisNCT07067463 · 2026-03-23 · 1 site observation
RECRUITING
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast CancerNCT07173751 · 2025-10-30 · 1 site observation
RECRUITING
DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-AdjustmentNCT07158164 · 2025-08-27 · 1 site observation
RECRUITING
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's DiseaseNCT06808984 · 2025-06-09 · 1 site observation
RECRUITING
Non-Invasive Preeclampsia Screening and BiobankNCT06643741 · 2025-02-02 · 1 site observation
RECRUITING
Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast CancerNCT06518837 · 2024-10-30 · 1 site observation
RECRUITING
RADIANT: Pre-op Radiation With Abemaciclib and LetrozoleNCT06139107 · 2024-08-22 · 1 site observation
RECRUITING
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)NCT06433752 · 2024-07-22 · 1 site observation
RECRUITING
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate CancerNCT05946213 · 2023-12-14 · 1 site observation
RECRUITING
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25NCT05879926 · 2023-10-18 · 1 site observation
RECRUITING
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung CancerNCT05624996 · 2023-07-12 · 1 site observation
RECRUITING
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabNCT05812807 · 2023-06-14 · 1 site observation
RECRUITING
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialNCT05564377 · 2023-04-07 · 1 site observation
RECRUITING
ATATcH Alternating Treatment Plans for Advanced CancerNCT05358548 · 2022-04-28 · 1 site observation
RECRUITING
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerNCT04181060 · 2020-12-28 · 1 site observation
RECRUITING
Pilot Trial of Preop Partial Radiation in Breast Cancer PatientsNCT07178665 · 2025-09-02 · 1 site observation
SUSPENDED
Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam TrialNCT06671912 · 2025-02-19 · 1 site observation
SUSPENDED
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic DiseaseNCT06760637 · 2025-01-06 · 1 site observation
ACTIVE_NOT_RECRUITING
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the BrainNCT06500455 · 2024-12-12 · 1 site observation
ACTIVE_NOT_RECRUITING
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and InflammationNCT05636176 · 2023-05-08 · 1 site observation
TERMINATED
G7 Freedom Constrained Vivacit-E LinersNCT05587244 · 2023-05-08 · 1 site observation
ENROLLING_BY_INVITATION
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung StudyNCT05633602 · 2023-03-14 · 1 site observation
ACTIVE_NOT_RECRUITING
Ocrelizumab Discontinuation in Relapsing Multiple SclerosisNCT05285891 · 2023-02-07 · 1 site observation
ACTIVE_NOT_RECRUITING
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung CancerNCT05198830 · 2022-12-15 · 1 site observation
ACTIVE_NOT_RECRUITING
Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)NCT05241860 · 2022-11-21 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerNCT05382286 · 2022-07-25 · 1 site observation
ACTIVE_NOT_RECRUITING
CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early StageNCT05333874 · 2022-04-06 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast CancerNCT05132582 · 2022-03-07 · 1 site observation
ACTIVE_NOT_RECRUITING
A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) ElevationNCT05090371 · 2022-03-02 · 1 site observation
ACTIVE_NOT_RECRUITING
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance TrialNCT05050084 · 2021-12-06 · 1 site observation
ACTIVE_NOT_RECRUITING
Spatz3 Adjustable Balloon System® (Spatz3) Post Approval StudyNCT05086302 · 2021-12-03 · 2 site observations
COMPLETED
Radiation Therapy Boost Before Surgery for the Treatment of Non-metastatic Breast CancerNCT04871516 · 2021-05-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Effect of Disease Modifying Therapy on Antibody Response to COVID19 Vaccination in Multiple SclerosisNCT04834401 · 2021-03-22 · 1 site observation
COMPLETED
18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA)NCT04647214 · 2021-03-03 · 1 site observation
COMPLETED
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD TrialNCT04457596 · 2021-03-02 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Diroximel Fumarate in the Real-World SettingNCT04746976 · 2021-03-01 · 1 site observation
TERMINATED
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT TrialNCT04513717 · 2021-01-21 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple SclerosisNCT04544449 · 2020-10-26 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)NCT04436744 · 2020-09-04 · 1 site observation
COMPLETED
NCI COVID-19 in Cancer Patients, NCCAPS StudyNCT04387656 · 2020-06-05 · 1 site observation
ACTIVE_NOT_RECRUITING
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung CancerNCT04092283 · 2020-04-29 · 1 site observation
ACTIVE_NOT_RECRUITING
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE TrialNCT04134260 · 2020-04-16 · 1 site observation
ACTIVE_NOT_RECRUITING
Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B)NCT04285346 · 2020-04-08 · 1 site observation
COMPLETED
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted TherapyNCT04266249 · 2020-03-13 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast CancerNCT03975647 · 2019-10-02 · 1 site observation
ACTIVE_NOT_RECRUITING
Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate CancerNCT04253483 · 2019-07-17 · 1 site observation
ACTIVE_NOT_RECRUITING
Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung CancerNCT03906071 · 2019-07-15 · 1 site observation
TERMINATED
Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerNCT03778931 · 2019-05-10 · 1 site observation
COMPLETED
Long-term Safety and Efficacy Extension Trial of Bimatoprost SRNCT03891446 · 2019-03-27 · 1 site observation
COMPLETED
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]NCT03734029 · 2018-12-27 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.